Cost-effectiveness for prevention of thromboembolism by anticoagulants in non-valvular atrial fibrillation: additional analysis from the Hokuriku˗Plus AF Registry View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-01-05

AUTHORS

Masakazu Yamagishi, Toyonobu Tsuda, Takeshi Kato, Hiroshi Furusho, Kenshi Hayashi

ABSTRACT

Although benefits of direct oral anticoagulants (DOAC) for treatment of non-valvular atrial fibrillation (AF) were well demonstrated, few data exist regarding cost-effectiveness between DOAC and warfarin uses in real-world clinical practice. Therefore, we estimated total cost of treatment for AF by authorized cardiologists in Japan. We studied consecutive 617 anticoagulated non-valvular AF patients (418 men, mean age 68.8, 54% warfarin) consulted by authorized cardiologists. The mean time in therapeutic range of warfarin was 71.8%. Under these conditions, we calculated the cost of anticoagulants, laboratory examination, and hospitalization due to thromboembolism or bleeding during follow-up for 3.1 years. Thromboembolism occurred in 26 patients (4.2%, 1.3/100 person-year) and hemorrhagic events in 20 patients (3.2%, 1.0/100 person-year). There was no significant difference in the occurrence rate of thromboembolism (log rank P = 0.16) or hemorrhagic events (log rank P = 0.83) between these two groups. Importantly, warfarin group showed lower cost than DOAC group (117,361 ± 743,710 yen/year vs. 310,436 ± 1,075,639 yen/person, P = 0.009) in terms of cost including drug, medical check, and hospitalization. These results demonstrate that the total cost with warfarin can be lower than DOAC in treatment for AF by authorized cardiologists in Japan, although further prospective randomized cost calculation is necessary including post-discharge care fee. More... »

PAGES

1024-1030

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00380-018-01333-6

DOI

http://dx.doi.org/10.1007/s00380-018-01333-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1111158778

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30612144


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anticoagulants", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Atrial Fibrillation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Electrocardiography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hemorrhage", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hospitalization", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Japan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multivariate Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proportional Hazards Models", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Registries", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thromboembolism", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Warfarin", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Human Sciences, Osaka University of Human Sciences, Settsu, Japan", 
          "id": "http://www.grid.ac/institutes/grid.444772.6", 
          "name": [
            "Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, 13-1 Takara-machi, 920-8641, Kanazawa, Ishikawa, Japan", 
            "Department of Human Sciences, Osaka University of Human Sciences, Settsu, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamagishi", 
        "givenName": "Masakazu", 
        "id": "sg:person.01111610241.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111610241.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, 13-1 Takara-machi, 920-8641, Kanazawa, Ishikawa, Japan", 
          "id": "http://www.grid.ac/institutes/grid.9707.9", 
          "name": [
            "Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, 13-1 Takara-machi, 920-8641, Kanazawa, Ishikawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tsuda", 
        "givenName": "Toyonobu", 
        "id": "sg:person.01202615172.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202615172.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of System Biology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan", 
          "id": "http://www.grid.ac/institutes/grid.9707.9", 
          "name": [
            "Department of System Biology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kato", 
        "givenName": "Takeshi", 
        "id": "sg:person.01013234345.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013234345.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of System Biology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan", 
          "id": "http://www.grid.ac/institutes/grid.9707.9", 
          "name": [
            "Department of System Biology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Furusho", 
        "givenName": "Hiroshi", 
        "id": "sg:person.01207412256.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207412256.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, 13-1 Takara-machi, 920-8641, Kanazawa, Ishikawa, Japan", 
          "id": "http://www.grid.ac/institutes/grid.9707.9", 
          "name": [
            "Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, 13-1 Takara-machi, 920-8641, Kanazawa, Ishikawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hayashi", 
        "givenName": "Kenshi", 
        "id": "sg:person.0762321530.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762321530.31"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2019-01-05", 
    "datePublishedReg": "2019-01-05", 
    "description": "Although benefits of direct oral anticoagulants (DOAC) for treatment of non-valvular atrial fibrillation (AF) were well demonstrated, few data exist regarding cost-effectiveness between DOAC and warfarin uses in real-world clinical practice. Therefore, we estimated total cost of treatment for AF by authorized cardiologists in Japan. We studied consecutive 617 anticoagulated non-valvular AF patients (418 men, mean age 68.8, 54% warfarin) consulted by authorized cardiologists. The mean time in therapeutic range of warfarin was 71.8%. Under these conditions, we calculated the cost of anticoagulants, laboratory examination, and hospitalization due to thromboembolism or bleeding during follow-up for 3.1\u00a0years. Thromboembolism occurred in 26 patients (4.2%, 1.3/100\u00a0person-year) and hemorrhagic events in 20 patients (3.2%, 1.0/100\u00a0person-year). There was no significant difference in the occurrence rate of thromboembolism (log rank P\u2009=\u20090.16) or hemorrhagic events (log rank P\u2009=\u20090.83) between these two groups. Importantly, warfarin group showed lower cost than DOAC group (117,361\u2009\u00b1\u2009743,710\u00a0yen/year vs. 310,436\u2009\u00b1\u20091,075,639\u00a0yen/person, P\u2009=\u20090.009) in terms of cost including drug, medical check, and hospitalization. These results demonstrate that the total cost with warfarin can be lower than DOAC in treatment for AF by authorized cardiologists in Japan, although further prospective randomized cost calculation is necessary including post-discharge care fee.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00380-018-01333-6", 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.7534930", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1095887", 
        "issn": [
          "0910-8327", 
          "1615-2573"
        ], 
        "name": "Heart and Vessels", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "34"
      }
    ], 
    "keywords": [
      "direct oral anticoagulants", 
      "non-valvular atrial fibrillation", 
      "atrial fibrillation", 
      "hemorrhagic events", 
      "non-valvular AF patients", 
      "real-world clinical practice", 
      "cost of anticoagulants", 
      "prevention of thromboembolism", 
      "warfarin group", 
      "DOAC group", 
      "oral anticoagulants", 
      "AF patients", 
      "AF Registry", 
      "therapeutic range", 
      "laboratory examinations", 
      "medical check", 
      "thromboembolism", 
      "clinical practice", 
      "anticoagulants", 
      "patients", 
      "warfarin", 
      "mean time", 
      "cardiologists", 
      "hospitalization", 
      "care fees", 
      "significant differences", 
      "fibrillation", 
      "treatment", 
      "occurrence rate", 
      "group", 
      "total cost", 
      "registry", 
      "prevention", 
      "Additional analyses", 
      "drugs", 
      "examination", 
      "events", 
      "years", 
      "differences", 
      "benefits", 
      "rate", 
      "Japan", 
      "terms of cost", 
      "practice", 
      "data", 
      "time", 
      "cost calculation", 
      "fees", 
      "analysis", 
      "cost", 
      "results", 
      "conditions", 
      "check", 
      "low cost", 
      "range", 
      "terms", 
      "calculations"
    ], 
    "name": "Cost-effectiveness for prevention of thromboembolism by anticoagulants in non-valvular atrial fibrillation: additional analysis from the Hokuriku\u02d7Plus AF Registry", 
    "pagination": "1024-1030", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1111158778"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00380-018-01333-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30612144"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00380-018-01333-6", 
      "https://app.dimensions.ai/details/publication/pub.1111158778"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:04", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_807.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00380-018-01333-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00380-018-01333-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00380-018-01333-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00380-018-01333-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00380-018-01333-6'


 

This table displays all metadata directly associated to this object as RDF triples.

238 TRIPLES      20 PREDICATES      103 URIs      95 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00380-018-01333-6 schema:about N05f8e67166014340ad9ae018debc6034
2 N0e23ceeaeb61467db5c21fbea10cf233
3 N0f163ab59a7f410a9d7615e6a7a2cea1
4 N1134678b09124ec3bea0752a0d33f174
5 N19867c5dddd1478484bc2a5a758480bb
6 N5069c8d57e2b40e0b7d1f0ea1ba4fe5a
7 N510d95b6ec634c4eb62e8376b891a85e
8 N538ff10cad29476eaf9fcee8878b9461
9 N580a114978a84a08b25a8bb1ea7f43e5
10 N5cb41a155070469ea192dba974131ad0
11 N6ee43c6e5fbf41e093d2b1b7d815901f
12 N6fd7a1fb7c384953b60aa19abe49919b
13 N90866bd6a36a4f71b68d71063100225e
14 Na313abeb05b642a29f60e961b30373d6
15 Nb4345174ae3741e692d67e978673c339
16 Nb5a43ae52838489cab84b0fd529a5533
17 Nd361d2bd6f14482ebd5020fff6a8f34b
18 Ndbbe301c95f542fa8eb994b0faddcb14
19 Ne2916629b57543228229f0d58fe72bb1
20 Ne89dbf12311d4782941e1f613abc8db3
21 Ne8ca659be9994775b686bec76c737c30
22 anzsrc-for:11
23 anzsrc-for:1117
24 schema:author Ncf5831a6c5004dff87fee1bb74fef487
25 schema:datePublished 2019-01-05
26 schema:datePublishedReg 2019-01-05
27 schema:description Although benefits of direct oral anticoagulants (DOAC) for treatment of non-valvular atrial fibrillation (AF) were well demonstrated, few data exist regarding cost-effectiveness between DOAC and warfarin uses in real-world clinical practice. Therefore, we estimated total cost of treatment for AF by authorized cardiologists in Japan. We studied consecutive 617 anticoagulated non-valvular AF patients (418 men, mean age 68.8, 54% warfarin) consulted by authorized cardiologists. The mean time in therapeutic range of warfarin was 71.8%. Under these conditions, we calculated the cost of anticoagulants, laboratory examination, and hospitalization due to thromboembolism or bleeding during follow-up for 3.1 years. Thromboembolism occurred in 26 patients (4.2%, 1.3/100 person-year) and hemorrhagic events in 20 patients (3.2%, 1.0/100 person-year). There was no significant difference in the occurrence rate of thromboembolism (log rank P = 0.16) or hemorrhagic events (log rank P = 0.83) between these two groups. Importantly, warfarin group showed lower cost than DOAC group (117,361 ± 743,710 yen/year vs. 310,436 ± 1,075,639 yen/person, P = 0.009) in terms of cost including drug, medical check, and hospitalization. These results demonstrate that the total cost with warfarin can be lower than DOAC in treatment for AF by authorized cardiologists in Japan, although further prospective randomized cost calculation is necessary including post-discharge care fee.
28 schema:genre article
29 schema:isAccessibleForFree false
30 schema:isPartOf N1d3b8caa981243aab67f908fbe245b79
31 N761a39451a1c42c28004cc08eb2338b4
32 sg:journal.1095887
33 schema:keywords AF Registry
34 AF patients
35 Additional analyses
36 DOAC group
37 Japan
38 analysis
39 anticoagulants
40 atrial fibrillation
41 benefits
42 calculations
43 cardiologists
44 care fees
45 check
46 clinical practice
47 conditions
48 cost
49 cost calculation
50 cost of anticoagulants
51 data
52 differences
53 direct oral anticoagulants
54 drugs
55 events
56 examination
57 fees
58 fibrillation
59 group
60 hemorrhagic events
61 hospitalization
62 laboratory examinations
63 low cost
64 mean time
65 medical check
66 non-valvular AF patients
67 non-valvular atrial fibrillation
68 occurrence rate
69 oral anticoagulants
70 patients
71 practice
72 prevention
73 prevention of thromboembolism
74 range
75 rate
76 real-world clinical practice
77 registry
78 results
79 significant differences
80 terms
81 terms of cost
82 therapeutic range
83 thromboembolism
84 time
85 total cost
86 treatment
87 warfarin
88 warfarin group
89 years
90 schema:name Cost-effectiveness for prevention of thromboembolism by anticoagulants in non-valvular atrial fibrillation: additional analysis from the Hokuriku˗Plus AF Registry
91 schema:pagination 1024-1030
92 schema:productId N380952948c80441d9193a5de99a27a9f
93 N7468216f8f8e4fdbb661365c11296af6
94 Nb711ce645b0b4f9398737aef62ceb9f7
95 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111158778
96 https://doi.org/10.1007/s00380-018-01333-6
97 schema:sdDatePublished 2022-09-02T16:04
98 schema:sdLicense https://scigraph.springernature.com/explorer/license/
99 schema:sdPublisher Ne315e5bf79be42afbb1046e82affb737
100 schema:url https://doi.org/10.1007/s00380-018-01333-6
101 sgo:license sg:explorer/license/
102 sgo:sdDataset articles
103 rdf:type schema:ScholarlyArticle
104 N05f8e67166014340ad9ae018debc6034 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Female
106 rdf:type schema:DefinedTerm
107 N0e23ceeaeb61467db5c21fbea10cf233 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Hospitalization
109 rdf:type schema:DefinedTerm
110 N0f163ab59a7f410a9d7615e6a7a2cea1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Hemorrhage
112 rdf:type schema:DefinedTerm
113 N1134678b09124ec3bea0752a0d33f174 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Thromboembolism
115 rdf:type schema:DefinedTerm
116 N19867c5dddd1478484bc2a5a758480bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Cost-Benefit Analysis
118 rdf:type schema:DefinedTerm
119 N1d3b8caa981243aab67f908fbe245b79 schema:issueNumber 6
120 rdf:type schema:PublicationIssue
121 N380952948c80441d9193a5de99a27a9f schema:name doi
122 schema:value 10.1007/s00380-018-01333-6
123 rdf:type schema:PropertyValue
124 N5069c8d57e2b40e0b7d1f0ea1ba4fe5a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Aged
126 rdf:type schema:DefinedTerm
127 N510d95b6ec634c4eb62e8376b891a85e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Adult
129 rdf:type schema:DefinedTerm
130 N538ff10cad29476eaf9fcee8878b9461 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Male
132 rdf:type schema:DefinedTerm
133 N580a114978a84a08b25a8bb1ea7f43e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Administration, Oral
135 rdf:type schema:DefinedTerm
136 N5cb41a155070469ea192dba974131ad0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Middle Aged
138 rdf:type schema:DefinedTerm
139 N6ee43c6e5fbf41e093d2b1b7d815901f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Registries
141 rdf:type schema:DefinedTerm
142 N6fd7a1fb7c384953b60aa19abe49919b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Multivariate Analysis
144 rdf:type schema:DefinedTerm
145 N7468216f8f8e4fdbb661365c11296af6 schema:name dimensions_id
146 schema:value pub.1111158778
147 rdf:type schema:PropertyValue
148 N761a39451a1c42c28004cc08eb2338b4 schema:volumeNumber 34
149 rdf:type schema:PublicationVolume
150 N856588181bac4a34aa143b988a1d7933 rdf:first sg:person.0762321530.31
151 rdf:rest rdf:nil
152 N8faba2e0c6c4415086c608aa51d09fae rdf:first sg:person.01207412256.17
153 rdf:rest N856588181bac4a34aa143b988a1d7933
154 N90866bd6a36a4f71b68d71063100225e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Atrial Fibrillation
156 rdf:type schema:DefinedTerm
157 N932f80a57bf846bb83adb6cfb2bb20b2 rdf:first sg:person.01013234345.46
158 rdf:rest N8faba2e0c6c4415086c608aa51d09fae
159 Na313abeb05b642a29f60e961b30373d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Proportional Hazards Models
161 rdf:type schema:DefinedTerm
162 Nb4345174ae3741e692d67e978673c339 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Humans
164 rdf:type schema:DefinedTerm
165 Nb5a43ae52838489cab84b0fd529a5533 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Electrocardiography
167 rdf:type schema:DefinedTerm
168 Nb711ce645b0b4f9398737aef62ceb9f7 schema:name pubmed_id
169 schema:value 30612144
170 rdf:type schema:PropertyValue
171 Ncf5831a6c5004dff87fee1bb74fef487 rdf:first sg:person.01111610241.58
172 rdf:rest Ncfcc93fc1cba4466827a89c0cfebba92
173 Ncfcc93fc1cba4466827a89c0cfebba92 rdf:first sg:person.01202615172.67
174 rdf:rest N932f80a57bf846bb83adb6cfb2bb20b2
175 Nd361d2bd6f14482ebd5020fff6a8f34b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Warfarin
177 rdf:type schema:DefinedTerm
178 Ndbbe301c95f542fa8eb994b0faddcb14 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Aged, 80 and over
180 rdf:type schema:DefinedTerm
181 Ne2916629b57543228229f0d58fe72bb1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Prospective Studies
183 rdf:type schema:DefinedTerm
184 Ne315e5bf79be42afbb1046e82affb737 schema:name Springer Nature - SN SciGraph project
185 rdf:type schema:Organization
186 Ne89dbf12311d4782941e1f613abc8db3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Japan
188 rdf:type schema:DefinedTerm
189 Ne8ca659be9994775b686bec76c737c30 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Anticoagulants
191 rdf:type schema:DefinedTerm
192 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
193 schema:name Medical and Health Sciences
194 rdf:type schema:DefinedTerm
195 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
196 schema:name Public Health and Health Services
197 rdf:type schema:DefinedTerm
198 sg:grant.7534930 http://pending.schema.org/fundedItem sg:pub.10.1007/s00380-018-01333-6
199 rdf:type schema:MonetaryGrant
200 sg:journal.1095887 schema:issn 0910-8327
201 1615-2573
202 schema:name Heart and Vessels
203 schema:publisher Springer Nature
204 rdf:type schema:Periodical
205 sg:person.01013234345.46 schema:affiliation grid-institutes:grid.9707.9
206 schema:familyName Kato
207 schema:givenName Takeshi
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013234345.46
209 rdf:type schema:Person
210 sg:person.01111610241.58 schema:affiliation grid-institutes:grid.444772.6
211 schema:familyName Yamagishi
212 schema:givenName Masakazu
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111610241.58
214 rdf:type schema:Person
215 sg:person.01202615172.67 schema:affiliation grid-institutes:grid.9707.9
216 schema:familyName Tsuda
217 schema:givenName Toyonobu
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202615172.67
219 rdf:type schema:Person
220 sg:person.01207412256.17 schema:affiliation grid-institutes:grid.9707.9
221 schema:familyName Furusho
222 schema:givenName Hiroshi
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207412256.17
224 rdf:type schema:Person
225 sg:person.0762321530.31 schema:affiliation grid-institutes:grid.9707.9
226 schema:familyName Hayashi
227 schema:givenName Kenshi
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762321530.31
229 rdf:type schema:Person
230 grid-institutes:grid.444772.6 schema:alternateName Department of Human Sciences, Osaka University of Human Sciences, Settsu, Japan
231 schema:name Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, 13-1 Takara-machi, 920-8641, Kanazawa, Ishikawa, Japan
232 Department of Human Sciences, Osaka University of Human Sciences, Settsu, Japan
233 rdf:type schema:Organization
234 grid-institutes:grid.9707.9 schema:alternateName Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, 13-1 Takara-machi, 920-8641, Kanazawa, Ishikawa, Japan
235 Department of System Biology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
236 schema:name Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, 13-1 Takara-machi, 920-8641, Kanazawa, Ishikawa, Japan
237 Department of System Biology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
238 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...